106 related articles for article (PubMed ID: 11764067)
1. Current status of HER2 testing: caught between a rock and a hard place.
Schnitt SJ; Jacobs TW
Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
[No Abstract] [Full Text] [Related]
2. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
3. Human epidermal growth factor receptor 2 testing in breast cancer.
Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
[No Abstract] [Full Text] [Related]
4. The clinical evaluation of HER-2 status: which test to use?
Bartlett J; Mallon E; Cooke T
J Pathol; 2003 Apr; 199(4):411-7. PubMed ID: 12635130
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Egervari K; Szollosi Z; Nemes Z; Kaczur V
Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
[No Abstract] [Full Text] [Related]
6. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies.
Arena V; Pennacchia I; Monego G; Carbone A; Capelli A
J Clin Oncol; 2010 Feb; 28(5):e83-4; author reply e85-8. PubMed ID: 20065180
[No Abstract] [Full Text] [Related]
7. Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
Moelans CB; van Diest PJ
J Natl Cancer Inst; 2011 Apr; 103(8):698-9. PubMed ID: 21406657
[No Abstract] [Full Text] [Related]
8. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L
Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693
[No Abstract] [Full Text] [Related]
9. The importance of accuracy in HER2 testing.
Gonzalez-Angulo AM
Clin Adv Hematol Oncol; 2012 Aug; 10(8):529-31. PubMed ID: 23073051
[No Abstract] [Full Text] [Related]
10. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
Tubbs RR; Stoler MH
Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
[No Abstract] [Full Text] [Related]
11. Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
Hugh J; Barley R; Dabbagh L
Mod Pathol; 2001 Mar; 14(3):263. PubMed ID: 11266538
[No Abstract] [Full Text] [Related]
12. Inconsistency of HER2 test raises questions.
Tuma RS
J Natl Cancer Inst; 2007 Jul; 99(14):1064-5. PubMed ID: 17623788
[No Abstract] [Full Text] [Related]
13. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 testing recommendation.
Raji A
J Clin Oncol; 2007 Sep; 25(25):4020-1; author reply 4021-3. PubMed ID: 17761990
[No Abstract] [Full Text] [Related]
15. [Standardization of HER2 testing in gastric cancer].
Long XY; Bu H; Liu JP
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):645-8. PubMed ID: 22177257
[No Abstract] [Full Text] [Related]
16. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
17. [Quality control of HER2 immunohistochemistry--results from a Hungarian study].
Cserni G; Kálmán E; Kulka J; Orosz Z; Udvarhelyi N; Krenács T
Magy Onkol; 2007; 51(1):23-9. PubMed ID: 17417672
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.
Altaha R; Crowell E; Hobbs G; Higa G; Abraham J
Cancer; 2005 Feb; 103(3):442-3. PubMed ID: 15578684
[No Abstract] [Full Text] [Related]
19. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
Schmidt C
J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
[No Abstract] [Full Text] [Related]
20. Immunohistochemical assays for HER2 overexpression.
Maia DM
J Clin Oncol; 1999 May; 17(5):1650. PubMed ID: 10334562
[No Abstract] [Full Text] [Related]
[Next] [New Search]